Trial Profile
A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results of CALGB 50403 study presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 04 Dec 2018 Results assessing efficacy of Bortezomib in patients with mantle cell lymphoma, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 08 Dec 2015 Interim results (5-year PFS) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.